NL-OMON35433已完成不适用
Double-blind, placebo- and active-controlled, randomized, single-ascending dose study to investigate the tolerability, safety, pharmacokinetics, and pharmacodynamics of ACT-462206 in healthy male subjects - First-in-man study of single, ascending doses of ACT-462206
Actelion Pharmaceuticals0 个研究点目标入组 64 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Signed informed consent prior to any study-mandated procedure.;- Healthy male subjects aged between 18 and 45 years (inclusive) at screening.;- Hematology, clinical chemistry, and urinalysis results not deviating from the normal range to a clinically relevant extent at screening.;- No clinically significant findings on physical examination at screening.;- Body mass index (BMI) between 18.0 and 28.0 kg/m2 (inclusive) at screening.;- Systolic blood pressure (SBP) 100-145 mmHg, diastolic blood pressure (DBP) 50-90 mmHg, and heart rate (HR) 45-90 bpm (inclusive) measured at screening on the dominant arm after 5 minutes in supine position.;- 12-lead electrocardiogram (ECG) without clinically relevant abnormalities in supine position at screening.;- Negative results from urine drug screen at screening.;- Ability to communicate well with the investigator in the local language, and to understand and comply with the requirements of the study.
排除标准
- •- Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.;- Veins unsuitable for intravenous (i.v.) puncture on either arm (e.g., veins that are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture).;- Treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John*s Wort) within 2 weeks prior to (first) study drug administration.;- Treatment with another investigational drug within 3 months prior to screening or having participated in more than four investigational drug studies within 1 year prior to screening.;- History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening.;- History or clinical evidence of any disease, and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drugs.;- Excessive caffeine consumption, defined as >= 800 mg per day at screening.;- Smoking within 3 months prior to screening and inability to refrain from smoking during the course of the study (from screening to End-of-Study [EOS]).;- Loss of 250 mL or more of blood, or an equivalent amount of plasma, within 3 months prior to screening.;- Positive results from the hepatitis serology, except for vaccinated subjects or subjects with past but resolved hepatitis, at screening.;- Positive results from the HIV serology at screening.;- Known hypersensitivity to any excipients of the drug formulations.;- Modified Swiss Narcolepsy Scale total score < 0 or history of narcolepsy or cataplexy. ;- Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.;- Legal incapacity or limited legal capacity at screening.
研究者
相似试验
进行中（未招募）
1 期
Randomized, double-blind, placebo and active controlled study of the activity ofSAR407899A single-dose on the ability to increase duration of penile rigidity,under experimental condition, in patients with mild to moderate erectiledysfunction - RHOKETMild to moderate erectile dysfunctionMedDRA version: 11.1Level: LLTClassification code 10061461Term: <Manually entered code. Term in E.1.1>EUCTR2009-009936-56-FRsanofi-aventis recherche et développement24
进行中（未招募）
不适用
Double-blind, randomised, placebo and active controlled, parallel group study to evaluate the analgesic effect of a single oral administration of four different combination doses of DKP.TRIS with TRAM.HCl in comparison with the single agents, on moderate to severe pain following impacted third mandibular molar tooth extraction - NDModerate to severe pain following impacted third mandibular molar tooth extraction.MedDRA version: 9.1Level: LLTClassification code 10044017EUCTR2010-022798-32-ITMENARINI RICERCHE S.P.A.600
进行中（未招募）
不适用
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label ExtensionEstudio aleatorizado, en doble ciego, controlado con producto activo y con placebo, de grupos paralelos y multicéntrico, para evaluar la eficacia y la seguridad de distintas dosis de CG5503 en formulación de liberación inmediata en el tratamiento del dolor agudo consecuencia de la cirugía de artroplastia total de cadera, seguido por una extensión abierta de carácter voluntariopainMedDRA version: 8.1Level: LLTClassification code 10033371Term: PainEUCTR2006-004513-18-ESJohnson & Johnson Pharmaceutical Research & Development, L.L.C.1,100
进行中（未招募）
1 期
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label ExtensiopainMedDRA version: 8.1Level: LLTClassification code 10033371Term: PainEUCTR2006-004513-18-FRJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
进行中（未招募）
不适用
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label ExtensioEUCTR2006-004513-18-FIJohnson & Johnson Pharmaceutical Research & Development, L.L.C.1,100